Does recombinant human erythropoietin not only treat anemia but reduce postpartum (emotional) distress as well?
Based on the established rhEPO treatment of anemia in endstage renal failure, which results in improved quality of life, and on the clinical observation that patients with postpartum anemia treated with rhEPO seemed to gain a more stable mood, we inferred that there is a beneficial side-effect of rhEPO on postpartum blues. The aim of this study was to test the hypotheses 1) that postpartum anemia aggravates, and 2) that treatment of postpartum anemia with rhEPO reduces maternity blues. The results show that on the fifth day postpartum anemic patients score consistently worse than nonanemic women on the Symptom Checklist SCL-90-R, indicating more symptoms and distress in general, and also more symptoms characteristic of maternity blues (p < 0.05). On a "Blues Questionnaire," postpartum anemia expresses itself with a reduced "well-being" (p < 0.001). Thus, our first hypothesis was verified. There were no differences by the fifth day postpartum between anemic patients receiving either rhEPO or placebo. Our second hypothesis was thus not confirmed within this limited time. We conclude as clinicians that postpartum anemia should be treated effectively to reduce distress and hence the risk for postpartum affective disorders. Follow-up studies after rhEPO treatment beyond the first week post partum are needed. In addition, in investigations on postpartum affective disorders, the hemoglobin concentration should be considered.
Meyer
J W
JW
Psychiatric Clinic, University Hospital of Zurich, Switzerland.
Eichhorn
K H
KH
Vetter
K
K
Christen
S
S
Schleusner
E
E
Klos
A
A
Huch
A
A
Huch
R
R
D000740:Anemia / Q000188:drug therapy*; D004311:Double-Blind Method; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D010919:Placebos; D011247:Pregnancy; D011446:Prospective Studies; D011618:Psychotic Disorders / Q000517:prevention & control*; D011644:Puerperal Disorders / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000627:therapeutic use
D006454:Hemoglobins; D010919:Placebos; D011994:Recombinant Proteins; D004921:Erythropoietin